PALM SPRINGS, Calif., Dec. 5 Dynamic AlertLimited (OTC Bulletin Board: DYMC) is pleased to announce that it has nowidentified its target markets for its pharmaceutical product line-up. Themodalities will include a lozenge with some capacity for enhancing rapid onsetthrough oromucosal absorption, topical applications, such as lotions andsalves, and various products for internal use. Some products will havespecific uses, while others may treat a range of problems. In keeping withboth the historic medical uses of cannabis and the new scientificunderstanding of how cannabinoids work, Dynamic's cannabinoid pharmaceuticalswill be targeting a wide-variety of serious needs such as:
President & CEO, Richard Cowan, states, "We are certainly pleased at thespeed in which our business model is rolling out. The potential market sizefor some of these products is obviously very large. When multiplied by thevarious categories and compounded by multiple country rollouts, we arecertainly undertaking a major pharmaceutical venture. Our success will bedetermined by the successes of our patients. Our strategy for success includesincreasing the speed of bringing each product to market by using amulti-pronged approach. It is important to bear in mind that our ability toreceive licensing fees for the various products will not have to wait onapproval for use. Moreover, conventional measures of the variouspharmaceutical markets do not offer a fair measure of the potential forcannabis-based medicines. For example, the huge cost of treating diseases suchas MRSA is not measured by the cost of specific pharmaceuticals. Moreover,there is no simple metric for the value of reducing a patient's need fordebilitating opiates. Consequently, we are extremely excited to bring suchimportant medical advances to the people who need them most."
In each of these areas, cannabis has been proven to work, so Dynamic willhave targeted formulations, which the Company plans to release via one or moreof the four types of pharmaceutical product categories targeted:
Director and Chief Science Officer, Dr. Robert Melamede, stated, "There isan enormous need for these products. Recent advances in science have openedthe door to develop, produce, and commercialize a variety of effective wholeplant cannabinoid-based pharmaceutical products with a wide variety ofimportant applications. Although cannabis has been used medicinally forthousands of years, until very recently little was known about how it actuallyworked. Our team of scientists will develop more effective ways to produce andcommercialize the production of whole plant cannabinoid-based pharmaceuticalproducts. Even today new uses for cannabis are being found, such as the recentdiscovery that topical cannabis preparations can be effective against MRSA,the deadly antibiotic-resistant flesh-eating disease."
You should not place undue reliance on forward-looking statements in thispress release. This press release contains forward-looking statements thatinvolve risks and uncertainties. Words such as "will," "anticipates,""believes," "plans," "goal," "expects," "future," "intends" and similarexpressions are used to identify these forward-looking statements. Actualresults could differ materially from those anticipated in theseforward-looking statements for many reasons, including the risks we face asdescribed in this press release.1. Neuro-muscular disorders, such as MS. 2. Neuropathic pain, related to spinal cord injuries, as well as conditions such as AIDS/HIV and the side-effects of its medications, etc. for which opiates are not very effective. 3. Chronic pain, to reduce or eliminate patients' dependence on opiates. 4. Respiratory inflammation, related to both infections such as influenza and to autoimmune diseases such as asthma. 5. Cancer, including pain management, control of nausea resulting from chemotherapy as well as loss of appetite related to the disease itself. 6. Also control of cancer in conditions such as Pheochromocytoma. 7. Digestive illnesses, such as gastroesophageal reflux disease (GERDS), Crohn's Disease and irritable bowel syndrome. 8. Dermatological infections, such as MRSA (flesh eating disease). 9. Sleep disorders.
SOURCE Dynamic Alert Limited